(NASDAQ: RCKT) Rocket Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.5%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.08%.
Rocket Pharmaceuticals's revenue in 2024 is $0.On average, 5 Wall Street analysts forecast RCKT's revenue for 2024 to be $2,437,098,390, with the lowest RCKT revenue forecast at $72,403,398, and the highest RCKT revenue forecast at $9,399,771,197. On average, 5 Wall Street analysts forecast RCKT's revenue for 2025 to be $16,683,281,564, with the lowest RCKT revenue forecast at $2,090,648,129, and the highest RCKT revenue forecast at $29,486,283,998.
In 2026, RCKT is forecast to generate $23,406,208,618 in revenue, with the lowest revenue forecast at $23,406,208,618 and the highest revenue forecast at $23,406,208,618.